Eli Lilly Has Good News About Its Alzheimer's Drug. What It Means for Biogen.
The fate of two experimental drugs to treat early stage Alzheimer’s sent shares of Biogen on a wild ride this week. Analysts at Truist raised their price target on Lilly (ticker: LLY) to $200 from $182 after the company revealed optimistic results from a stage 2 trial of its donanemab treatment, which was found to slow the decline in cognition and function in Alzheimer’s patients. The new price target implies an 11% gain from the current price. Lilly shares jumped on Monday after the news, but settled back on Tuesday, falling 3.2%. It is up 6.9% this year compared to a 1.3% gain ...